CI 988
Alternative Names: PD 134308Latest Information Update: 27 Aug 2001
At a glance
- Originator Pfizer
- Class Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Cancer; Pain; Peptic ulcer
Most Recent Events
- 27 Aug 2001 No-Development-Reported for Anxiety disorders in United Kingdom (Unknown route)
- 27 Aug 2001 No-Development-Reported for Cancer in Australia (Unknown route)
- 27 Aug 2001 No-Development-Reported for Pain in France (Unknown route)